Immunoglobulin G - Biotest Pharmaceuticals

Drug Profile

Immunoglobulin G - Biotest Pharmaceuticals

Alternative Names: Bivigam; Immunoglobulin liquid intravenous - Biotest Pharmaceuticals; IVIG - Biotest Pharmaceuticals; IVIG - Nabi Biopharmaceuticals; NABI-IVIG

Latest Information Update: 21 Jan 2016

Price : $50

At a glance

  • Originator Nabi Biopharmaceuticals
  • Developer Biotest Pharmaceuticals
  • Class Immunoglobulin isotypes
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Immunodeficiency disorders

Most Recent Events

  • 19 Jan 2016 Immunoglobulin G licensed to Kedrion Biopharma in USA
  • 31 Jan 2013 Launched for Immunodeficiency disorders in USA (IV) - First global launch
  • 20 Dec 2012 Registered for Immunodeficiency disorders in USA (IV) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top